Literature DB >> 10340407

Rapid ex vivo expansion of human umbilical cord hematopoietic progenitors using a novel culture system.

H Kawada1, K Ando, T Tsuji, Y Shimakura, Y Nakamura, J Chargui, M Hagihara, H Itagaki, T Shimizu, S Inokuchi, S Kato, T Hotta.   

Abstract

Cell numbers limit the widespread clinical use of cord blood (CB) for gene therapy and marrow replacement in adults; a simple and effective method for ex vivo expansion of CB primitive progenitor cells (PPC) is required. Recently, the combination of thrombopoietin (TPO) and Flk-2/Flt-3 ligand (FL-2) was reported to support slow proliferation of CB-PPC in stroma-free liquid culture. We established a novel culture system in which the murine stromal cell line HESS-5 dramatically supports the rapid expansion of cryopreserved CB-PPC in synergy with TPO/FL-2. Furthermore, while HESS-5 cells directly adhered to human progenitors during culture, the cultured human cells could easily be harvested without contamination by HESS-5 cells. Within 7 days of culture, a 100-fold increase in CD34bright/CD38dim cells was obtained in serum-containing culture. When HESS-5 cells were physically separated from human progenitor cells in the presence of TPO/FL-2, synergy was blocked, suggesting that HESS-5 cells support proliferation of PPC by direct cell-to-cell interaction. The hematopoietic-supportive effects of this xenogeneic coculture system were then assessed in a very short-term (5 days) serum-free culture. Expansion was further enhanced by addition of stem cell factor (SCF) or interleukin-3 (IL-3). As a result, a 50- to 100-fold increase in CD34bright/CD38dim cells was noted. Colony-forming units in culture (CFU-C) and mixed colonies (CFU-GEMM) were enhanced by 10- to 30-fold and 10- to 20-fold, respectively. Moreover, generation of long-term-culture-initiating cells (LTC-IC) from CD34bright/CD38dim cells was amplified by 25-fold. The severe-combined immunodeficient (SCID) mouse-repopulating cell (SRC) assay confirmed extensive ability of the expanded cells to reconstitute long-term hematopoiesis. These results indicate that this xenogeneic coculture system, in combination with human cytokines, can rapidly generate PPC from cryopreserved CB.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10340407     DOI: 10.1016/s0301-472x(99)00012-0

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  15 in total

1.  The comparison of different protocols for expansion of umbilical-cord blood hematopoietic stem cells.

Authors:  Mihaela Chivu; Carmen C Diaconu; Coralia Bleotu; Irina Alexiu; Lorelei Brasoveanu; C Cernescu
Journal:  J Cell Mol Med       Date:  2004 Apr-Jun       Impact factor: 5.310

Review 2.  Process challenges relating to hematopoietic stem cell cultivation in bioreactors.

Authors:  Marcin Kowalczyk; Kathryn Waldron; Penia Kresnowati; Michael K Danquah
Journal:  J Ind Microbiol Biotechnol       Date:  2011-03-09       Impact factor: 3.346

3.  Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.

Authors:  Jiro Kikuchi; Daisuke Koyama; Taeko Wada; Tohru Izumi; Peter O Hofgaard; Bjarne Bogen; Yusuke Furukawa
Journal:  J Clin Invest       Date:  2015-10-26       Impact factor: 14.808

4.  Preclinical transplantation and safety of HS/PCs expanded from human umbilical cord blood.

Authors:  Chun-Juan Guo; Ying Gao; Di Hou; Dong-Yan Shi; Xiang-Min Tong; Dan Shen; Yong-Mei Xi; Jin-Fu Wang
Journal:  World J Stem Cells       Date:  2011-05-26       Impact factor: 5.326

5.  Cocultivation of umbilical cord blood CD34+ cells with retro-transduced hMSCs leads to effective amplification of long-term culture-initiating cells.

Authors:  Chun-Gang Xie; Jin-Fu Wang; Ying Xiang; Li-Yan Qiu; Bing-Bing Jia; Li-Juan Wang; Guo-Zhong Wang; Guo-Ping Huang
Journal:  World J Gastroenterol       Date:  2006-01-21       Impact factor: 5.742

Review 6.  Establishing humanized mice using stem cells: maximizing the potential.

Authors:  D Bernard; M Peakman; A C Hayday
Journal:  Clin Exp Immunol       Date:  2008-04-24       Impact factor: 4.330

7.  Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.

Authors:  Shmuel Yaccoby; Michele J Wezeman; Maurizio Zangari; Ronald Walker; Michele Cottler-Fox; Danna Gaddy; Wen Ling; Rinku Saha; Bart Barlogie; Guido Tricot; Joshua Epstein
Journal:  Haematologica       Date:  2006-02       Impact factor: 9.941

8.  Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.

Authors:  Jiro Kikuchi; Daisuke Koyama; Harumi Y Mukai; Yusuke Furukawa
Journal:  Int J Hematol       Date:  2014-04-06       Impact factor: 2.490

9.  In vitro expansion of fetal liver hematopoietic stem cells.

Authors:  Rashmi Bhardwaj; Lalit Kumar; Deepika Chhabra; N K Mehra; Atul Sharma; Sujata Mohanty; Vinod Kochupillai
Journal:  Sci Rep       Date:  2021-06-04       Impact factor: 4.379

10.  High concentrations of L-ascorbic acid specifically inhibit the growth of human leukemic cells via downregulation of HIF-1α transcription.

Authors:  Hiroshi Kawada; Mitsuyo Kaneko; Masakazu Sawanobori; Tomoko Uno; Hideyuki Matsuzawa; Yoshihiko Nakamura; Hiromichi Matsushita; Kiyoshi Ando
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.